Inovio Pharmaceuticals Inc(NASDAQ:INO) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $8.514M. Analysts estimated a revenue of $5.950M. The revenues were 43.09% above the estimates. Earnings per share were $-0.35. The reported EPS was below estimates by -16.67%. Analysts had estimated an EPS of $-0.3.
Inovio Pharmaceuticals Inc (INO) shares turned negative on Fridays trading session with the shares closing down -0.08 points or -1.29% at a volume of 11,96,379. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $6.22. The peak price level was also seen at $6.22 while the days lowest was $6.035. Finally the shares closed at $6.13. The 52-week high of the shares is $11.69 while the 52-week low is $5.85. According to the latest information available, the market cap of the company is $454 M.
Several Insider Transactions has been reported to the SEC. On Aug 30, 2016, Niranjan Sardesai (Chief Operating Officer) sold 21,800 shares at $9.30 per share price.Also, On Jun 29, 2016, Morton Collins (director) purchased 10,000 shares at $9.13 per share price.On May 18, 2016, Simon X Benito (director) sold 6,250 shares at $10.37 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovio Pharmaceuticals Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31 2014 Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers prostate cancer breast/lung/pancreatic cancer hepatitis C virus (HCV) hepatitis B virus (HBV) HIV influenza and Ebola. With its immunotherapy platform consisting of SynCon products as well as its CELLECTRA electroporation delivery technology Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.